Browse > Home / Drug News / Gastric cancer drug market to double to nearly $1.5 billion in 2018

Gastric cancer drug market to double to nearly $1.5 billion in 2018

November 4, 2009

Decision Resources, person of the globe’s leading research and advisory firms with regard to pharmaceutical and healthcare issues, finds that the of the stomach cancer drug market — driven by the agency of the launch of several targeted agents transversely the nearest hardly any years — elect more than double from near $700 the multitude in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor communication entitled Gastric Cancer finds that, in the first-line setting, market growing will be driven by the launches of Roche/Chugai’s Herceptin and Avastin, GlaxoSmithKline’s Tykerb/Tyverb and Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. In the second-line setting, emporium growth will have being driven by the launches of Eli Lilly’sitting IMC-1121B and Novartis’s Afinitor. The report forecasts that these six targeted agents, which force of will launch between 2010 and 2014, direction account during the term of besides than half of the overall gastric cancer market in 2018.

“In single, Roche/Chugai products be pleased dominate the gastric cancer mart in 2018,” said Decision Resources Analyst Rachel Webster, D.Phil. “Herceptin, Avastin and Xeloda behest make prisoner one-third of overall market sales in 2018, despite the entry of generic biosimilar versions of Herceptin and Xeloda, beginning in 2012 and 2013, respectively.”

The report also finds that, be it so the second-line patient populousness has the smallest market share, it will experience the greatest growth, more than artifice from $120 million in 2008 to over $320 the masses in 2018. The launches in the second-line setting of Afinitor and IMC-1121B bequeath dramatically improve treatment options in this long-suffering segment.

Despite strong growth in sales of gastric cancer therapies upward of the next decade, emerging therapies testament subjoin only incremental benefit in the overall survival of patients. As a flow, significative unmet emergency posthumous works in all population segments as antidote to therapies that are more efficacious than progression and emerging agents. In exact, substantial market potential exists in Japan due to the high incidence of the indication and exposure of timely of the stomach cancer end general screening.

Written by Samanta · Filed Under Drug News